Actionable news
0
All posts from Actionable news
Actionable news in GBT: Global Blood Therapeutics Inc,

Global Blood Therapeutics Announces Upcoming Presentation of Data Supporting Sickle Cell Disease Program at the 58th American Society of Hematology (ASH) Annual Meeting & Exposition Conference

SOUTH SAN FRANCISCO, Calif., Nov 03, 2016 (GLOBE NEWSWIRE via COMTEX) --

Global Blood Therapeutics, Inc. (GBT) GBT, -11.05% a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders with significant unmet need, today announced that new data supporting its GBT440 program in sickle cell disease (SCD) will be presented at the 58 [th] American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego. The poster presentations will include additional data from the ongoing Phase 1/2 GBT440-001 trial of GBT440 including dosing of 900 mg per day in SCD patients for up to 6 months, and the metabolism of GBT440 in healthy subjects. The poster presentations will also include the methodology utilized to develop the Patient Reported Outcome (PRO) tool that will be used in the HOPE (Hemoglobin Oxygen Affinity Modulation to Inhibit HbS PolymErization) Study. Patient enrollment of variant SCD genotypes in the GBT440-001 trial is ongoing, and will support the inclusion of patients with variant genotypes in the HOPE Study.

GBT440 is being developed as an oral, once-daily therapy for patients with sickle cell disease (SCD). GBT440 works by increasing hemoglobin's affinity for oxygen. Since oxygenated sickle hemoglobin does not polymerize, GBT believes GBT440 blocks polymerization and the resultant sickling of red blood cells. With the potential to restore normal hemoglobin function and improve oxygen delivery, GBT believes that GBT440 may be capable of modifying the progression of SCD. The U.S. Food and Drug Administration (FDA) has granted GBT440 both fast track and orphan drug designations for the treatment of patients with SCD, in recognition of the critical need for new treatments. The pivotal HOPE Study will begin screening patients by December 2016.

The ASH abstracts are now available at www.hematology.org. The poster presentations will include additional data not available in the abstracts. Presentation details are as follows:

Poster Session: 114. Hemoglobinopathies, Excluding Thalassemia--Clinical Poster II
Abstract #2488: Long-Term Dosing in Sickle Cell Disease Subjects with GBT440, a Novel HbS Polymerization Inhibitor
Presenter: Dr. Jo Howard, Guy's and St Thomas'...


More